Is RANKL inhibition both anti-resorptive and anabolic in rheumatoid arthritis?
A small peptide, OP3-4, blocks receptor activator of NF-κB from binding to its ligand, receptor activator of NF-κB ligand (RANKL), and was reported recently to inhibit bone resorption, promote bone formation and protect cartilage in a preclinical rheumatoid arthritis model. The latter effects may re...
Main Authors: | Sims, Natalie A., Romas, Evange |
---|---|
Format: | Online |
Language: | English |
Published: |
BioMed Central
2015
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650503/ |
Similar Items
-
Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment
by: Iuliani, Michele, et al.
Published: (2015) -
Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects
by: Garcia-Gomez, Antonio, et al.
Published: (2012) -
Atorvastatin inhibits osteoclastogenesis by decreasing the expression of RANKL in the synoviocytes of rheumatoid arthritis
by: Kim, Jeong Yeon, et al.
Published: (2012) -
Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis
by: Braun, Tobias, et al.
Published: (2011) -
Expression of osteoprotegerin and its ligands, RANKL and TRAIL, in rheumatoid arthritis
by: Remuzgo-Martínez, Sara, et al.
Published: (2016)